Document is current
Any future updates will be listed below
-
Authors
Larsen, Lucas Møller
Winther, Sine Voss
Kørvel-Hanquist, Asbjørn
Marott, Sarah C. W.
Landt, Eskild M.
Homøe, Preben
Nordestgaard, Børge G.
Dahl, Morten
-
Funding
Funding for this research was provided by:
Alpha-1 Foundation (612336)
Novo Nordisk Fonden (NNF19OC0058811)
Region Sjælland (R19A341B233)
Copenhagen University
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 3 February 2025
First Online: 14 March 2025
Declarations
:
: B.G. Nordestgaard has consultancies with Amarin, Akcea, Amgen, AstraZeneca, Denka Seiken, Kowa, Novartis, Novo Nordisk, and Silence Therap. M. Dahl has consultancies with Grifols, Takeda, and Chiesi. No conflict of interests exists for L.M. Larsen, S.V. Winther, N. Korsbæk, A. Kørvel-Hanquist, S.C.W. Marott, E.M. Landt and P. Homøe.
: Registry-based studies are exempt from approval from an ethics committee and informed consent requirements under Danish legislation. The Copenhagen General Population study was approved by Herlev and Gentofte Hospital and Danish ethics committee (identification number H-KF-01–144/01) and was conducted according to the declaration of Helsinki.
